LABROOTS: CANCER RESEARCH & ONCOLOGY, OCTOBER 2018

MOBILE PAP TEST: A PREDICATABLE FUTURE FOR CANCER PREVENTION



Dr. Olivera Markovic, Global Academy for Women's Health, Rockville, MD USA, E-mail: gawh@markpap,com



WELCOME

TO MODERN MARVELS

- Since 1945 when Dr. Georges Papanicolaou showed how to detect early lesions that can develop into cervical cancer, the Pap test became a standard for screening of cervical cancer worldwide and for timely removal of the suspect lesions.
- Almost a century later, the medicine has changed and the IT technology is becoming a predominant way of medical communication improving the accuracy of diagnosis and reducing the cost.
- This poster is showing a concept for a new strategy for cervical cancer screening based on Mobile telemedicine.
- Details may be found in the reference book, What Every Woman Should Know about Cervical Cancer (Springer, 2017)http://www.apringer.com/biomed/cancer/book/378-1-4020- 6936-9and at www.amazon.com



MARKPAP® SYSTEM™

Global Academy for Women's Health, Inc. is having a privilege to introduce to the Cancer Research & Oncology2018 Virtual Conference Poster Session, a new medical device, the MarkPap(r) System, which development is sponsored by BioSciCon, Inc. to facilitate global reversal of cervical cancer mortality trends by increasing the outreach among women at risk, improving the diagnostic accuracy and reducing the cost to make the System affordable in LMIC

(C) BioSciCon, 2018-2028

ASSAY including biomarker, cytopathology and HPV, plus home self collection

MARKPAP SYSTEM ADVANTAGE

- MarkPap System has addressed three important topics:
- 1. Outreach: Using Self-collection kit to increase the number of screened women
- 2. Accuracy: Using MEDYKO composite biomarker to reduce false positive and false negative readings
- 3. Cost affordability: Using IT technology including mobile telemedicine, to enable inter specialists on line communication reducing the cost and improving the accuracy.

(C) BioSciCon, 2018-2028

BIOMARKER ADVANTAGE

- MarkPap System introduces a new biomarker, MEDYKO. It is a composite biomarker including metabolic, morphologic and HPV disease markers, in instant presentation available for digital assessment and remote evaluation.
- An example is presented on the next slides

10/8/2018 (C) BioSciCon, 2018-2028

MARKPAP® SYSTEM **REPORT** POC Home test TCP MEDYKO INTERVENTION MOBILE REFERRAL **TELEMEDICINE** (C) BioSciCon, 2018-2028


BASIC TOOLS HOME

INDVIDUAL TESTING SELF-SPECIMEN COLLECTION KIT POINT-OF-CARE: DIAGNOSTIC INTERVENTION LABORATORY: DIAGNOSTIC KIT (MEDYKO-BIOMARKER, HPV, DNA) MOBILE TELEMEDICINE: PROTOCOL TCP MEDICAL CENTER – ITTHC - DIAGNOSIS & THERAPY

REFERENCE BOOK (www.amazon.com)

- This is the second updated and extended edition of our book published by Springer in
- This is a monograph-type text book with more than 500 pages, plenty of illustrations, explanation and guidance's for professional and nonprofessional audience.

10/8/2018



(C) BioSciCon, 2018-2028

BUSINESS OPTIONS

- The System is protected by a U.S. patent and International patent treaty.
- Different modules are in different stage of development, from initial to sales.
- Sponsor has opened free competition for investing into the project(s) and has offered equity investment into the trade organization MarkPap LLC.

10/8/2018 (C) BioSciCon, 2018-2028

MOBILE TELEMEDICINE



MarkPap[®] Mobile™